Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation

 Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation

Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation

Shots:

  • PureTech to receive $26M as an upfront including research funding & preclinical milestone, $200M as development and commercial milestones and royalties on sales. Boehringer to develop immune-oncology candidates after it enters to development stage by utilizing PureTech’s lymphatic targeting technology
  • The focus of the collaboration is to develop immuno-oncology candidates for gastrointestinal (GI) cancers administered directly to the gut lymphatics to potentially tune systemic and local immunity
  • PureTech’s lymphatic targeting technology is designed to enable the transport of drug directly into the lymphatic system when administered orally targeting cancer, inflammatory and autoimmune diseases

Click here to read full press release/ article | Ref: Puretech | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post